Aurinia Pharmaceuticals (AUPH) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Aurinia Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$235.13M

Latest Revenue (Q)

$57.19M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Aurinia Pharmaceuticals Revenue by Period

Aurinia Pharmaceuticals Revenue by Year

Date	Revenue	Change
2024-12-31	$235.13M	33.97%
2023-12-31	$175.51M	30.95%
2022-12-31	$134.03M	193.89%
2021-12-31	$45.60M	-9.00%
2020-12-31	$50.12M	15660.38%
2019-12-31	$318.00K	-31.32%
2018-12-31	$463.00K	10.24%
2017-12-31	$420.00K	142.77%
2016-12-31	$173.00K	-26.38%
2015-12-31	$235.00K	-15.47%
2014-12-31	$278.00K	-70.69%
2013-12-31	$948.56K	-84.60%
2012-12-31	$6.16M	563.90%
2011-12-31	$927.52K	-72.88%
2010-12-31	$3.42M	-15.59%
2009-12-31	$4.05M	4.52%
2008-12-31	$3.88M	66.05%
2007-12-31	$2.33M	-33.72%
2006-12-31	$3.52M	199.06%
2005-12-31	$1.18M	-7.51%
2004-12-31	$1.27M	-83.38%
2003-12-31	$7.66M	-35.71%
2002-12-31	$11.92M	124.97%
2001-12-31	$5.30M	486.77%
2000-11-30	$902.77K	-33.53%
1999-11-30	$1.36M	73.85%
1998-11-30	$781.25K	-

Aurinia Pharmaceuticals generated $235.13M in revenue during NA 2024, up 33.97% compared to the previous quarter, and up 73941.19% compared to the same period a year ago.

Aurinia Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-06-30	$57.19M	13.70%
2024-03-31	$50.30M	11.55%
2023-12-31	$45.09M	-17.28%
2023-09-30	$54.52M	31.38%
2023-06-30	$41.49M	20.59%
2023-03-31	$34.41M	21.01%
2022-12-31	$28.43M	-49.02%
2022-09-30	$55.78M	97.86%
2022-06-30	$28.19M	30.36%
2022-03-31	$21.63M	-7.60%
2021-12-31	$23.40M	59.57%
2021-09-30	$14.67M	121.56%
2021-06-30	$6.62M	624.29%
2021-03-31	$914.00K	-98.17%
2020-12-31	$50.03M	172417.24%
2020-09-30	$29.00K	-
2020-06-30	$29.00K	-3.33%
2020-03-31	$30.00K	3.45%
2019-12-31	$29.00K	-87.39%
2019-09-30	$230.00K	693.10%
2019-06-30	$29.00K	-3.33%
2019-03-31	$30.00K	3.45%
2018-12-31	$29.00K	-92.27%
2018-09-30	$375.00K	1193.10%
2018-06-30	$29.00K	-3.33%
2018-03-31	$30.00K	-3.23%
2017-12-31	$31.00K	6.90%
2017-09-30	$29.00K	-91.19%
2017-06-30	$329.00K	961.29%
2017-03-31	$31.00K	3.33%
2016-12-31	$30.00K	-3.23%
2016-09-30	$31.00K	-43.64%
2016-06-30	$55.00K	-3.51%
2016-03-31	$57.00K	-
2015-12-31	$57.00K	-
2015-09-30	$57.00K	-3.39%
2015-06-30	$59.00K	-4.84%
2015-03-31	$62.00K	-8.82%
2014-12-31	$68.00K	-5.56%
2014-09-30	$72.00K	1.41%
2014-06-30	$71.00K	5.97%
2014-03-31	$67.00K	-90.33%
2013-12-31	$692.64K	721.28%
2013-09-30	$84.34K	2.00%
2013-06-30	$82.69K	-5.47%
2013-03-31	$87.47K	1.47%
2012-12-31	$86.21K	-1.34%
2012-09-30	$87.38K	-1.26%
2012-06-30	$88.49K	-98.48%
2012-03-31	$5.81M	4745.76%
2011-12-31	$119.97K	-77.57%
2011-09-30	$534.84K	250.00%
2011-06-30	$152.81K	10.83%
2011-03-31	$137.87K	-53.70%
2010-12-31	$297.75K	12.95%
2010-09-30	$263.62K	-81.35%
2010-06-30	$1.41M	-2.37%
2010-03-31	$1.45M	-12.58%
2009-12-31	$1.66M	72.55%
2009-09-30	$959.87K	55.20%
2009-06-30	$618.46K	-4.42%
2009-03-31	$647.03K	592.40%
2008-12-31	$93.45K	-96.54%
2008-09-30	$2.70M	386.86%
2008-06-30	$555.12K	-1.32%
2008-03-31	$562.52K	-8.72%
2007-12-31	$616.27K	-

Aurinia Pharmaceuticals generated $57.19M in revenue during Q2 2024, up 13.70% compared to the previous quarter, and up 166.21% compared to the same period a year ago.

Aurinia Pharmaceuticals Revenue Breakdown

Aurinia Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
License, Collaboration and Royalty Revenue	$18.95M	$16.98M	-	-	-
Product	$216.19M	$158.53M	$103.47M	$45.49M	-
License	-	-	$30.56M	$117.00K	$50.12M

Aurinia Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (91.94%), and License, Collaboration and Royalty Revenue (8.06%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Product	$57.58M	$55.50M	$55.03M	$48.07M	$42.31M	$40.78M	$41.10M	$34.34M	$28.33M	$25.50M	$28.15M	$21.49M	$23.38M	$14.64M	$6.59M	$30.00K
License, Royalty and Collaboration Revenue	-	$12.27M	$2.16M	$2.23M	$13.73M	$394.00K	$72.00K	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	-	-	-	$109.00K	$30.28M	$43.00K	$133.00K	$29.00K	$29.00K	$29.00K	$884.00K

Aurinia Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).

Aurinia Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
JAPAN	$25.04M	$17.55M	$31.48M	-	$50.00M
UNITED STATES	$210.09M	$157.96M	$102.46M	$45.49M	-
Other Country	-	-	$89.00K	$117.00K	-
CHINA	-	-	-	-	$118.00K

Aurinia Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (89.35%), and JAPAN (10.65%).

Aurinia Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
EXEL	Exelixis	$2.17B	$478.06M
SRPT	Sarepta Therapeutics	$1.90B	$362.93M
PTCT	PTC Therapeutics	$806.78M	$135.42M
AXSM	Axsome Therapeutics	$385.69M	$87.17M
AUPH	Aurinia Pharmaceuticals	$235.13M	$57.19M
MDGL	Madrigal Pharmaceuticals	$180.13M	$62.17M
BTAI	BioXcel Therapeutics	$2.27M	$1.10M
MCRB	Seres Therapeutics	-	-
AKRO	Akero Therapeutics	-	-
VKTX	Viking Therapeutics	-	-
TGTX	TG Therapeutics	-	$83.88M
HEPA	Hepion Pharmaceuticals	-	-
TERN	Terns Pharmaceuticals	-	-

AUPH Revenue FAQ

What is Aurinia Pharmaceuticals’s yearly revenue?

Aurinia Pharmaceuticals's yearly revenue for 2024 was $235.13M, representing an increase of 33.97% compared to 2023. The company's yearly revenue for 2023 was $175.51M, representing an increase of 30.95% compared to 2022. AUPH's yearly revenue for 2022 was $134.03M, representing an increase of 193.89% compared to 2021.

What is Aurinia Pharmaceuticals’s quarterly revenue?

Aurinia Pharmaceuticals's quarterly revenue for Q2 2024 was $57.19M, a 13.70% increase from the previous quarter (Q1 2024), and a 37.83% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $50.3M, a 11.55% increase from the previous quarter (Q4 2023), and a 46.19% increase year-over-year (Q1 2023). AUPH's quarterly revenue for Q4 2023 was $45.1M, a -17.28% decrease from the previous quarter (Q3 2023), and a 58.59% increase year-over-year (Q4 2022).

What is Aurinia Pharmaceuticals’s revenue growth rate?

Aurinia Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 75.43%, and for the last 5 years (2020-2024) was 369.16%.

What are Aurinia Pharmaceuticals’s revenue streams?

Aurinia Pharmaceuticals's revenue streams in c 24 are License, Collaboration and Royalty Revenue, and Product. License, Collaboration and Royalty Revenue generated $18.95M in revenue, accounting 8.06% of the company's total revenue, up 11.58% year-over-year. Product generated $216.19M in revenue, accounting 91.94% of the company's total revenue, up 36.37% year-over-year.

What is Aurinia Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Aurinia Pharmaceuticals was Product. This segment made a revenue of $216.19M, representing 91.94% of the company's total revenue.